The Government has committed up to £520 million in capital grants for life sciences manufacturing to help stimulate economic growth and build an NHS fit for the future.
Key details of the LSIMF:
Scope: The LSIMF will be UK-wide and sector-wide, offering capital grants covering 10-20% of project costs.
Focus areas for investment:
Human medicines – both active pharmaceutical ingredients (API) and finished drug products.
Medical diagnostics – for disease identification and monitoring.
MedTech products – including all types of medical devices related to human health.
Key scheme dates:
Open now for EOIs (Expressions of Interest)
April 2025: First grants awarded
Closing date: Open until funds are fully allocated
Eligibility criteria:
Company eligibility:
Must be a UK-registered, wholly private sector business.
Must be a product developer, a contract development manufacturing organisation, or a generics manufacturer.
Project eligibility:
Must have a total cost (including capital and non-capital costs) of at least £8 million.
Must be located in the UK.
Must be primarily a capital investment.
Must be a single-company investment (not a partnership between multiple companies or organisations).
Must focus on manufacturing human medicines, medical diagnostics, or MedTech products.
The fund is available for projects involving MHRA-licensed products or products in development that will seek an MHRA licence for commercial scaling, such as clinical trial manufacturing projects.
Find out more from Clive Owen LLP’s grants advisory team cliveowen.com
